Computational modeling and preclinical evaluation support targeting somatic instability for Huntington’s disease treatment.
RNA-seq (gene expression) · human · 104 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 104 samples: 96 distinct titles, 4 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE338964_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1496612 and SRA study SRP718811. Searching any of these in the dataset finder brings you back here.
How we read this: Read from 104 sample titles: 96 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9885670 01_1E6_AAV-miMSH3_rep1_7_days
- GSM9885671 02_1E6_AAV-miMSH3_rep2_7_days
- GSM9885672 03_1E6_AAV-miMSH3_rep3_7_days
- GSM9885673 04_1E6_AAV-miMSH3_rep4_7_days
- GSM9885674 05_1E5_AAV-miMSH3_rep1_7_days
- GSM9885675 06_1E5_AAV-miMSH3_rep2_7_days
- GSM9885676 07_1E5_AAV-miMSH3_rep3_7_days
- GSM9885677 08_1E5_AAV-miMSH3_rep4_7_days
- GSM9885678 09_1E4_AAV-miMSH3_rep1_7_days
- GSM9885679 10_1E4_AAV-miMSH3_rep2_7_days
- GSM9885680 11_1E4_AAV-miMSH3_rep3_7_days
- GSM9885681 12_1E4_AAV-miMSH3_rep4_7_days
- GSM9885682 13_1E6_AAV-TFP1_rep1_7_days
- GSM9885683 14_1E6_AAV-TFP1_rep2_7_days
- GSM9885684 15_1E6_AAV-TFP1_rep3_7_days
- GSM9885685 16_1E6_AAV-TFP1_rep4_7_days
- GSM9885686 17_1E5_AAV-TFP1_rep1_7_days
- GSM9885687 18_1E5_AAV-TFP1_rep2_7_days
- GSM9885688 19_1E5_AAV-TFP1_rep3_7_days
- GSM9885689 20_1E5_AAV-TFP1_rep4_7_days
- GSM9885690 21_1E4_AAV-TFP1_rep1_7_days
- GSM9885691 22_1E4_AAV-TFP1_rep2_7_days
- GSM9885692 23_1E4_AAV-TFP1_rep3_7_days
- GSM9885693 24_1E4_AAV-TFP1_rep4_7_days
- GSM9885694 25_N_A_Vehicle_control_rep1_7_days
- GSM9885695 26_N_A_Vehicle_control_rep2_7_days
- GSM9885696 27_N_A_Vehicle_control_rep3_7_days
- GSM9885697 28_N_A_Vehicle_control_rep4_7_days
- GSM9885698 29_1E6_AAV-miMSH3_rep1_7_days
- GSM9885699 30_1E6_AAV-miMSH3_rep2_7_days
- GSM9885700 31_1E6_AAV-miMSH3_rep3_7_days
- GSM9885701 32_1E6_AAV-miMSH3_rep4_7_days
- GSM9885702 33_1E5_AAV-miMSH3_rep1_7_days
- GSM9885703 34_1E5_AAV-miMSH3_rep2_7_days
- GSM9885704 35_1E5_AAV-miMSH3_rep3_7_days
- GSM9885705 36_1E5_AAV-miMSH3_rep4_7_days
- GSM9885706 37_1E4_AAV-miMSH3_rep1_7_days
- GSM9885707 38_1E4_AAV-miMSH3_rep2_7_days
- GSM9885708 39_1E4_AAV-miMSH3_rep3_7_days
- GSM9885709 40_1E4_AAV-miMSH3_rep4_7_days
+ 64 more — browse all 104 samples with per-sample file links →
- GSE309827 Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models 17 samples shares preclinical, evaluation, targeting
- GSE241936 Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models [RNA-Seq2] 36 samples shares preclinical, targeting
- GSE269743 Assessment and Evaluation of Contemporary Approaches for Astrocyte Differentiation from hiPSCs: A Modeling Paradigm for Alzheimer's Disease 26 samples shares evaluation, modeling
- GSE282752 Clinical evaluation of a functional combinatorial precision medicine platform to predict treatment outcomes and enhance combination therapy design in soft tissue sarcomas 24 samples shares evaluation, treatment
- GSE337350 Brain-sensing synNotch-CAR T-cells enable precise targeting and clearance of diffuse midline glioma in multiple preclinical models 24 samples shares preclinical, targeting
- GSE240496 Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models [RNA-Seq] 24 samples shares preclinical, targeting
- GSE301688 Preclinical Evaluation of the Efficacy of a Cyclin-dependent Kinase Inhibitor Ribociclib in Combination with Letrozole Against Patient-Derived Glioblastoma Cells 18 samples shares preclinical, evaluation
- GSE255459 Computational modeling integrating transcriptomic and vulnerability responses can predict suppressors of cell death as candidate targets for cancer therapy 18 samples shares computational, modeling
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.